SHELLY MCCORMICK: Open Payments
NPI 1467131573 · LAYTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,985 in 124 payments from 28 companies in 2025. Trend: 2023 $145 · 2024 $1,755 · 2025 $1,985
Food & beverage: $1,985
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $370 |
| Lilly USA, LLC | 11 | $160 |
| Otsuka America Pharmaceutical, Inc. | 12 | $155 |
| Novo Nordisk Inc | 11 | $136 |
| Novartis Pharmaceuticals Corporation | 6 | $128 |
| Axsome Therapeutics, Inc. | 5 | $99 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $90 |
| Aimmune Therapeutics, Inc. | 5 | $89 |
| GlaxoSmithKline, LLC. | 4 | $74 |
| Amgen Inc. | 4 | $69 |
Products named: REXULTI, VRAYLAR, MOUNJARO, LEQVIO, QULIPTA, CAPLYTA, ZENPEP, Sunosi.
Industry payments across UT — which companies pay providers there.
